Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vanda Pharmaceuticals
This study will also evaluate the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject participated in the preceding placebo-controlled Phase 3 study ANB019-301 and completed at least the Week 1 visit of the ANB019-301 study without the use of rescue/prohibited medication for GPP
Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
You may not be if
Use of prohibited medications between the last visit of the ANB019-301 study and the Day 1 visit of the ANB019-302 study
Clareo Health | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
